Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

LIPOMED GmbH
Hegenheimer strasse 2, D - 79576 Weil/Rhein, Germany
Telephone: +49 7621 1693 472
Fax: +49 7621 1693474
E-mail: Lipomed@lipomed.com
WWW: http://www.lipomed.com
Medical Information Direct Line: +49 7761 559222
Medical Information e-mail: lipomed@lipomed.com
Medical Information e-mail: save@lipomed.com
Customer Care direct line: +44 (0)1494 761 523
Medical Information Fax: +49 7761 559223

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 16/06/2010
SPC LITAK 2mg/ml solution for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/06/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5 - Pharmacological Properties
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   01-Dec-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


2. Qualitative and quantitative composition

4.2 Posology and method of administration

 

Posology

Elderly

Renal and hepatic impairment

Method of administration

Self administration by the patient

 

4.3 Contraindications

4.4 Special warnings and special precautions for use

 

Haematological toxicity

Renal and hepatic impairment

Elderly

Fertility

 

4.5 Interactions with other medicinal products and other forms of interactions

4.6 Pregnancy and lactation

4.7 Effects on ability to drive and use machines

4.8.    Undesirable effects

4.9.    Overdose

5.1    Pharmacodynamic properties

5.2    Pharmacokinetic properties

5.3    Preclinical safety data

6.1    List of excipients

6.6    Special precautions for disposing and other handling

7.0  Marketing Authorisation Holder ( new address )

9.0  Data of first authorisation/renewal of the authorisation

 

 

 

 

 

 

 

 

 

 

 

 

 
Updated on 07/11/2008 and displayed until 16/06/2010
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   20-Feb-2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Date of revision of text from 14th April 2004 to 20th of Feb 2006
Updated on 05/02/2008 and displayed until 07/11/2008
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
  cladribine